Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial

Digestive Diseases and Sciences

Volumn 53, Issue 1, 2008, Pages 108-115

  Talley, Nicholas J ^a,b   Kellow, John E ^a   Boyce, Philip ^d   Tennant, Christopher ^c   Huskic, Sandy ^a   Jones, Michael ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

Antidepressant; Irritable bowel syndrome; Randomized trial

Indexed keywords

CITALOPRAM; IMIPRAMINE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; BEDTIME DOSAGE; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT RESPONSE; VARIANCE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIPRAMINE; IRRITABLE BOWEL SYNDROME; MALE; PATIENT SATISFACTION; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 37249086163     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9830-4     Document Type: Article

References (26)

1. Drossman DA, Whitehead WE, Camilleri M (1997) Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 112:2120-2137
2. Talley N, Spiller RC (2002) Irritable bowel syndrome: a little understood organic bowel disease? Lancet 360:555-564
3. Thompson W, Longstreth G, Drossman D, Heaton K, Irvine E, Muller-Lissner S (1999) Functional bowel disorders and functional abdominal pain. Gut 45:43-47
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480-1491
5. Cremonini F, Talley NJ (2005) Irritable bowel syndrome: epidemiology, natural history, health-care seeking and emerging risk factors. Gastroenterol Clin North Am 34:189-204
6. Whitehead WE, Burnett CK, Cook EW, Taub E (1996) Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 41:2248-2253
7. Talley N, Gabriel S, Harmsen W, Zinsmeister A, Evans R (1995) Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 109:1736-1741
8. Quartero A, Meineche-Schmidt V, Muris JW, Rubin G, de Wit N (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev CD003460
9. Talley NJ (2003) Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 56:362-369
10. Koloski N, Talley N, Boyce P (2001) Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 96:1340-1349
11. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S (2004) Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 72:1100-1113
12. Clouse RE (1994) Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 39:2352-2363
13. Clouse RE, Lustman PJ, Geisman RA, Alpers DH (1994) Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 8:409-416
14. Gorard DA, Libby GW, Farthing MJG (1994) Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8:159-166
15. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR (1999) Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13:1149-1159
16. Guy W (1976) ECDEU assessment manual for psychopharmacology publication ADM 76-338. U.S. Department of Health Education, Welfare, Washington D.C., pp 217-22
17. Boyce P, Gilchrist J, Talley NJ, Rose D (2000) Cognitive-behaviour therapy as a treatment for irritable bowel syndrome: a pilot study. Aust NZ J Psych 34:300-309
18. Drossman DA, Li Z, Toner BB, Diamant NE, Creed FH, Thompson D, Read NW, Babbs C, Barreiro M, Bank L et al (1995) Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 40:986-995
19. Crawford JR, Henry JD, Crombie C, Taylor EP (2001) Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 40:429-434
20. Grayson D (1989) Latent trait analysis of Eysenck Personality Questionnaire. J Psychol Res 20:217-235
21. Ware JEJ, Gandek B (1998) Overview of the SF-36 health survey and the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 51:903-912
22. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJO (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130:1538-1551
23. Drossman D, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI (2003) Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125:19-31
24. Kuiken SD, Tytgat GN, Boeckxstaens GE (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastoenterol Hepatol 1:219-228
25. Tack J, Broekaert D, Fischler B, Oudenhove LV, Gevers AM, Janssens J (2006) A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55:1095-1103
26. Vahedi H, Merat S, Rashidioon A, Choddoosi A, Malekzadeh R (2005) The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Therap 22:381-385